西藏药业：佐利替尼于今年上半年正式商业化

Core Viewpoint - The management of Tibet Pharmaceutical held a performance briefing for the first half of 2025, highlighting the commercialization of the drug Zolbetuximab by its subsidiary, Chentai Pharmaceutical, which is specifically designed for advanced non-small cell lung cancer with CNS metastasis [1] Group 1: Product Overview - Zolbetuximab is the world's first drug targeting advanced non-small cell lung cancer (NSCLC) with CNS metastasis, achieving significant results in clinical trials [1] - It is the only EGFR tyrosine kinase inhibitor (EGFR-TKI) designed with a non-blood-brain barrier efflux protein substrate, demonstrating a 100% ability to penetrate the blood-brain barrier [1] Group 2: Commercialization and Financial Impact - Zolbetuximab was officially commercialized in the first half of this year, and preparations for medical insurance negotiations are underway [1] - The expected revenue from Zolbetuximab this year is not anticipated to have a significant impact on the company's overall financial performance [1]